FRACTYL HEALTH INC. - COMMON STOCK

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

06 May 2025 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

28 Apr 2025 15:30:00 By Nasdaq GlobeNewswire

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

01 Apr 2025 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

03 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

24 Feb 2025 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

31 Jan 2025 07:01:00 By Nasdaq GlobeNewswire

Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

12 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

09 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Participate in the Upcoming December Conferences

26 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 15:05:42 By Nasdaq GlobeNewswire

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

04 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024

04 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

29 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

28 Oct 2024 06:00:56 By Nasdaq GlobeNewswire

Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference

24 Sep 2024 06:00:58 By Nasdaq GlobeNewswire

Fractyl Health to Participate in Upcoming September Investor Conferences

03 Sep 2024 06:00:52 By Nasdaq GlobeNewswire

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

14 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure

08 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

07 Aug 2024 06:00:21 By Nasdaq GlobeNewswire